Skip Navigation

European Heart Journal 1980 1(3):157-163;
Copyright © 1980 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by LEJEMTEL, T. H.
Right arrow Articles by SONNENBLICK, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEJEMTEL, T. H.
Right arrow Articles by SONNENBLICK, E. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1980 The European Society of Cardiology

Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure*

T. H. LEJEMTEL, U. ELKAYAM, H. S. RIBNER, C. HELLMAN, J. STROM, W. FRISHMAN, J. STROBECK and E. H. SONNENBLICK

Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine 1300 Morris Park Avenue, Bronx, New York 10461, U.S.A.

Received 25 March 1980; .

Requests for reprints to: Thierry H. LeJemtel, M.D., Division of Cardiology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer Building-Room 715, Bronx, New York 10461, U.S.A.

Hydralazine, 200 to 400 mg daily, was administered orally to 20 consecutive patients with severe heart failure. After 24 h of continuous hydralazine therapy, an average fall in mean blood pressure of 9 mmHg (P < 0.01) was associated with an overall increase in cardiac index from 1.7 to 2.4 l/min/m2 (P < 0.001), and a reduction in pulmonary wedge pressure from 24 to 20 mmHg (P < 0.05). However, five of the 20 patients developed minimal or no changes in cardiac index while the remaining 15 demonstrated a rise in cardiac index of at least 30%. Initial systemic vascular resistance was significantly higher in patients without change in cardiac index than in those with an increase (2348 v. 1818 dyne.s.cm–5; P < 0.05), but could not be used to predict accurately the response to hydralazine therapy. Thus, hydralazine is generally beneficial in severe heart failure but the hemodynamic responses in individual subjects may vary. Hemodynamic monitoring is recommended in severely ill patients to evaluate responsiveness in anticipation of long-term maintenance therapy.

Key Words: Hydralazine • pulmonary capillary wedge pressure • cardiac index • systemic vascular resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.